| |
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Freedom-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
Nov 17, 2008
|
13.3 KB
|
| |
Conference Call to be Held at 9:00 a.m. Eastern Time on November 17, 2008
Silver Spring, MD, November 17, 2008: United Therapeutics Corporation (NASDAQ: UTHR) announced today the results of the FREEDOM-C trial of oral treprostinil, a sustained-release formulation of treprostinil, in pulmonary arterial hypertension (PAH). Pr...
|
|
|
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
Nov 17, 2008
|
72.2 KB
|
| |
INDIANAPOLIS, IN and SILVER SPRING, MD - Eli Lilly and Company (NYSE:LLY) and United Therapeutics Corporation (NASDAQ:UTHR) today announced that the two companies have entered into a license and a supply agreement related to the U.S. commercialization rights for the pulmonary arterial hypertension (PAH) indication of Lilly's molecule, tad...
|
|
|
United Therapeutics Reports Third Quarter 2008 Financial Results
Oct 30, 2008
|
15.5 KB
|
| |
SILVER SPRING, Md., Oct 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2008. Total revenues for the third quarter of 2008 were $75.0 million, up from $59.0 million for the third quarter of 2007. Net income for the...
|
|
|
United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
Oct 23, 2008
|
8.1 KB
|
| |
SILVER SPRING, Md., Oct 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2008 third quarter financial results before market open on Thursday, October 30, 2008.
United Therapeutics will host a half-hour teleconference on Thursday, October 30, 2008, ...
|
|
|
Inhaled Treprostinil New Drug Application Filed by FDA
Sep 3, 2008
|
7.5 KB
|
| |
SILVER SPRING, Md., Sept 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for inhaled treprostinil for the treatment of pulmona...
|
|
|
United Therapeutics Reports Second Quarter 2008 Financial Results
Jul 31, 2008
|
15.5 KB
|
| |
SILVER SPRING, Md., July 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended June 30, 2008.
Total revenues for the second quarter of 2008 were $68.6 million, up 32.3% from $51.8 million for the second quarter of 2007. Net income...
|
|
|
United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
Jul 24, 2008
|
8.1 KB
|
| |
SILVER SPRING, Md., July 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2008 second quarter financial results before the open of market on Thursday, July 31, 2008.
United Therapeutics will host a half-hour teleconference on Thursday, July 31, 200...
|
|
|
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Jun 30, 2008
|
12.3 KB
|
| |
SILVER SPRING, Md., June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary, Lung Rx, Inc., announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of an inhaled formulation of treprosti...
|
|
|
Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
May 21, 2008
|
15.3 KB
|
| |
SILVER SPRING, Md., May 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. today announced that data from seven presentations concerning the treatment of pulmonary arterial hypertension (PAH) with treprostinil were reported at the American Thoracic ...
|
|
|
Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
May 6, 2008
|
8.6 KB
|
| |
SILVER SPRING, Md., May 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. today announced that data related to the four different routes of administration of the drug, treprostinil, for the treatment of pulmonary arterial hypertension will be presen...
|
|
|
United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders
May 1, 2008
|
9.7 KB
|
| |
SILVER SPRING, Md., May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) (the Company) held its annual meeting of shareholders (the Annual Meeting) on April 29, 2008. The Company's shareholders voted to approve the election of Raymond Dwek, Roger Jeffs and Christopher Patusky as Class III dire...
|
|
|
United Therapeutics Reports First Quarter 2008 Financial Results
May 1, 2008
|
16.1 KB
|
| |
SILVER SPRING, Md., May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended March 31, 2008.
Total revenues for the first quarter of 2008 were $62.0 million, up 55% from $40.2 million for the first quarter of 2007. Net income for ...
|
|
|
United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
Apr 24, 2008
|
7.7 KB
|
| |
SILVER SPRING, Md., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2008 first quarter financial results before the open of market on Thursday, May 1, 2008.
United Therapeutics will host a half-hour teleconference on Thursday, May 1, 2008, a...
|
|
|
United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
Feb 19, 2008
|
54.7 KB
|
| |
• Total Annual Revenues of $210.9 Million...
|
|
|
United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
Feb 12, 2008
|
8.0 KB
|
| |
SILVER SPRING, Md., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2007 fourth quarter and annual financial results before the open of market on Tuesday, February 19, 2008.
United Therapeutics will host a half-hour teleconference on Tuesday, ...
|
|
|
Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
Dec 5, 2007
|
11.6 KB
|
| |
SILVER SPRING, Md. and WELLESLEY HILLS, Mass., Dec 05, 2007 /PRNewswire- FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly- owned subsidiary, Unither Pharmaceuticals, Inc., announced today the completion of their two pivotal trials of OvaRex(R) MAb for the treatment of advanced ovarian cancer. Preli...
|
|
|
United Therapeutics Reports Third Quarter 2007 Financial Results
Nov 1, 2007
|
19.3 KB
|
| |
SILVER SPRING, Md., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2007.
Total revenues for the third quarter of 2007 were $59.0 million, up 46% from $40.4 million for the third quarter of 2006. Pro forma ...
|
|
|
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Nov 1, 2007
|
15.6 KB
|
| |
SILVER SPRING, Md., Nov 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary, Lung Rx, Inc., announced today the completion of their TRIUMPH-1 Phase 3 trial of Viveta, an inhaled formulation of treprostinil, in pulmonary arterial hypertension (PAH). Preliminary ana...
|
|
|
Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
Oct 31, 2007
|
9.4 KB
|
| |
SILVER SPRING, Md., Oct 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary, Lung Rx, Inc., announced today that they will release the results of their TRIUMPH-1 Phase 3 trial of Viveta, an inhaled formulation of treprostinil, in pulmonary arterial hypertension (P...
|
|
|
United Therapeutics to Announce Third Quarter 2007 Financial Results Before Market Open on Thursday, November 1, 2007
Oct 25, 2007
|
7.5 KB
|
| |
SILVER SPRING, Md., Oct. 25 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR - News) announced today that it will release its 2007 third quarter financial results before market open on Thursday, November 1, 2007.
United Therapeutics will host a half-hour teleconference on Thursday, November 1, 2007, at 9:00 a.m. Eastern T...
|
|
|
United Therapeutics' Press Release Archive is furnished solely for historical purposes. Statements made in any release posted here speak only as of the date of such release. We do not undertake any obligation to update any information contained in any release. Our business, financial condition, results of operations and prospects may have changed since the date of any release posted here.
|
